This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cardica Reports Progress With MicroCutter XCHANGE™ 30 In Europe

REDWOOD CITY, Calif., June 6, 2012 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today reported that its MicroCutter XCHANGE™ 30, a cartridge-based cutting and stapling device with a five millimeter shaft diameter, has been used successfully during the last two months in over 100 deployments during more than 35 surgical procedures at six separate hospitals in Germany.

The XCHANGE 30 has been used in a variety of procedures including appendectomies, large and small bowel procedures, gastrectomies, as well as various types of lung resections. The procedures were performed by 14 different surgeons in a combination of laparoscopic and open techniques.  All patients were discharged with no adverse events related to the XCHANGE 30.

"The XCHANGE 30 with its small shaft diameter and versatility, especially during thoracoscopic lung procedures, is a great advancement in stapling technology," said Dr. Albert Linder, chief of thoracic surgery at the Bremen Ost Hospital in Germany. "This device reduces the amount of necessary tissue dissection and thereby reduces the risk of vessel injury and bleeding, substantially reduces the need for larger trocars and due to the large degree of articulation, improves access within the thoracic cavity."

"We have performed a number of appendectomies with the XCHANGE 30 using only 5 mm trocar ports, thereby reducing the invasiveness, pain and discomfort and improving cosmesis," said Dr. Haemmerle from the Sana Klinikum in Hameln, Germany.

Based on the success of the initial deployments and feedback from the surgeons performing the procedures, Cardica continues to make modifications to the XCHANGE 30 in its effort to ensure consistent reliability prior to resuming the clinical study to support its U.S. regulatory submission. Subsequent to resuming the trial, which the company expects will be in late June or early July, Cardica expects to book commercial sales in the third quarter of calendar 2012.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,853.93 -74.27 -0.41%
S&P 500 2,083.80 -5.66 -0.27%
NASDAQ 4,922.9830 -16.3440 -0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs